Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities

Eli Lilly & Co., adjustment to Net Income (loss)

USD $ in thousands

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net income (loss) (as reported) (204,100) 2,737,600  2,408,400  2,390,500  4,684,800 
Add: Change in net unrealized gains and losses on securities (126,300) 213,900  (89,600) (105,500) 132,700 
Net income (loss) (adjusted) (330,400) 2,951,500  2,318,800  2,285,000  4,817,500 

Top


Adjusted Ratios: Mark to Market Available-for-sale Securities (Summary)

Eli Lilly & Co., adjusted ratios

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net Profit Margin
Reported net profit margin -0.89% 12.90% 12.07% 12.19% 20.27%
Adjusted net profit margin -1.44% 13.91% 11.62% 11.65% 20.84%
Return on Equity (ROE)
Reported ROE -1.76% 19.54% 16.53% 15.55% 26.57%
Adjusted ROE -2.85% 21.07% 15.91% 14.86% 27.32%
Return on Assets (ROA)
Reported ROA -0.45% 7.05% 6.77% 6.43% 13.29%
Adjusted ROA -0.73% 7.61% 6.52% 6.15% 13.67%
Ratio Description The company
Adjusted net profit margin An indicator of profitability, calculated as adjusted net income divided by revenue. Eli Lilly & Co.'s adjusted net profit margin improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.
Adjusted ROE A profitability ratio calculated as adjusted net income divided by shareholders' equity. Eli Lilly & Co.'s adjusted ROE improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.
Adjusted ROA A profitability ratio calculated as adjusted net income divided by total assets. Eli Lilly & Co.'s adjusted ROA improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.

Top


Adjusted Net Profit Margin

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
As Reported
Net income (loss) (USD $ in thousands) (204,100) 2,737,600  2,408,400  2,390,500  4,684,800 
Revenue (USD $ in thousands) 22,871,300  21,222,100  19,958,700  19,615,600  23,113,100 
Net profit margin1 -0.89% 12.90% 12.07% 12.19% 20.27%
Adjusted: Mark to Market Available-for-sale Securities
Adjusted net income (loss) (USD $ in thousands) (330,400) 2,951,500  2,318,800  2,285,000  4,817,500 
Revenue (USD $ in thousands) 22,871,300  21,222,100  19,958,700  19,615,600  23,113,100 
Adjusted net profit margin2 -1.44% 13.91% 11.62% 11.65% 20.84%

2017 Calculations

1 Net profit margin = 100 × Net income (loss) ÷ Revenue
= 100 × -204,100 ÷ 22,871,300 = -0.89%

2 Adjusted net profit margin = 100 × Adjusted net income (loss) ÷ Revenue
= 100 × -330,400 ÷ 22,871,300 = -1.44%

Ratio Description The company
Adjusted net profit margin An indicator of profitability, calculated as adjusted net income divided by revenue. Eli Lilly & Co.'s adjusted net profit margin improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.

Top


Adjusted Return on Equity (ROE)

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
As Reported
Net income (loss) (USD $ in thousands) (204,100) 2,737,600  2,408,400  2,390,500  4,684,800 
Total Eli Lilly and Company shareholders' equity (USD $ in thousands) 11,592,200  14,007,700  14,571,300  15,373,200  17,631,400 
ROE1 -1.76% 19.54% 16.53% 15.55% 26.57%
Adjusted: Mark to Market Available-for-sale Securities
Adjusted net income (loss) (USD $ in thousands) (330,400) 2,951,500  2,318,800  2,285,000  4,817,500 
Total Eli Lilly and Company shareholders' equity (USD $ in thousands) 11,592,200  14,007,700  14,571,300  15,373,200  17,631,400 
Adjusted ROE2 -2.85% 21.07% 15.91% 14.86% 27.32%

2017 Calculations

1 ROE = 100 × Net income (loss) ÷ Total Eli Lilly and Company shareholders' equity
= 100 × -204,100 ÷ 11,592,200 = -1.76%

2 Adjusted ROE = 100 × Adjusted net income (loss) ÷ Total Eli Lilly and Company shareholders' equity
= 100 × -330,400 ÷ 11,592,200 = -2.85%

Ratio Description The company
Adjusted ROE A profitability ratio calculated as adjusted net income divided by shareholders' equity. Eli Lilly & Co.'s adjusted ROE improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.

Top


Adjusted Return on Assets (ROA)

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
As Reported
Net income (loss) (USD $ in thousands) (204,100) 2,737,600  2,408,400  2,390,500  4,684,800 
Total assets (USD $ in thousands) 44,981,000  38,805,900  35,568,900  37,178,200  35,248,700 
ROA1 -0.45% 7.05% 6.77% 6.43% 13.29%
Adjusted: Mark to Market Available-for-sale Securities
Adjusted net income (loss) (USD $ in thousands) (330,400) 2,951,500  2,318,800  2,285,000  4,817,500 
Total assets (USD $ in thousands) 44,981,000  38,805,900  35,568,900  37,178,200  35,248,700 
Adjusted ROA2 -0.73% 7.61% 6.52% 6.15% 13.67%

2017 Calculations

1 ROA = 100 × Net income (loss) ÷ Total assets
= 100 × -204,100 ÷ 44,981,000 = -0.45%

2 Adjusted ROA = 100 × Adjusted net income (loss) ÷ Total assets
= 100 × -330,400 ÷ 44,981,000 = -0.73%

Ratio Description The company
Adjusted ROA A profitability ratio calculated as adjusted net income divided by total assets. Eli Lilly & Co.'s adjusted ROA improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.

Top